A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment of patients with hepatocellular carcinoma that are candidates for locoregional therapies.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms NASIR-HCC
- 26 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 19 Dec 2017 Planned End Date changed from 11 Sep 2021 to 1 Oct 2019.